ICEECE2012 Poster Presentations Diabetes (248 abstracts)
Implementation of the principles of the personalized medicine in the clinical practice: a pilot study for type 2 diabetes
L. Zarina 1 , L. Tarasova 4 , L. Nikitina-Zake 4 , I. Kempa 4 , M. Cirse 4 , J. Klovins 4 , K. Geldnere 1, , I. Konrade 3 , A. Lejnieks 3 & V. Pirags 1,
1Pauls Stradins Clinical University Hospital, Riga, Latvia; 2University of Latvia, Riga, Latvia; 3Riga Stradins University, Riga, Latvia; 4Latvian Biomedical Research and Study Center, Riga, Latvia.
Background: Many patients with type 2 diabetes (T2D) are not reaching glycemic targets even by using different combinations of antidiabetic drugs, including insulin. On the other hand, intensified multidrug therapy is associated with increased risk of severe side effects and individualized selection of medication is essential. The aim of our study is to evaluate efficiency of personalized pharmacotherapy according to the genotype and phenotype of T2D patients.
Methods/design: 95 treatment naive T2D patients were involved in prospective clinical trial. Genotyping by GoldenGate Genotyping Assay with VeraCode technology (Illumina, Inc.) of 192 SNP in previously reported genes influencing T2D treatment efficiency and tolerability (OCT1,2,3, MATE1,2, PMAT and others) was performed in all patients.
Results: First results of treatment efficiency and tolerability are currently available in 61 patients. Decrease of the mean HbA1c from 7.7±2.0% to 6.7±0.8% and the mean BMI from 34.6±5.9 kg/m2 to 34.1±5.6 kg/m2 was measured. SNP located in region between genes SLC22A2 – SLC22A3 was associated with HbA1c decrease after 3 month metformin therapy and the commonly carried A allele was more often detected in patients who responded to metformin therapy. Unadjusted association test (P=9.29e−005, OR (CI 0.95)=4.971[2.163–11.43]) identified association between genetic polymorphisms and response to metformin therapy. Association maintained statistical significance after Bonferroni correction (P=0.01793).
Conclusions: Genotyping of large number of known polymorphisms in genes responsible for efficiency of T2D therapy may help to individualize treatment schemes. Genetic polymorphisms in SLC22A2 – SLC22A3 gene region are associated with efficiency of short-term metformin treatment.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This work was supported, however funding details unavailable.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more